Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry Roundtable

Richard K. Scher, Antonella Tosti, Warren S. Joseph, Tracey C. Vlahovic, Jesse Plasencia, Bryan C. Markinson, David M. Pariser

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Onychomycosis prevalence is expected to rise as the population ages and the prevalence of diabetes, peripheral vascular disease, and other significant risk factors rise. Until recently, treatment options were limited due to safety concerns with oral antifungals and low efficacy with available topical agents. Efinaconzole and tavaborole were approved by the FDA in 2014 for onychomycosis treatment and provide additional effective topical treatment options for patients with mild-to-moderate disease. Dermatologists and podiatrists both regularly treat onychomycosis, yet there are striking differences between specialties in approach to diagnosis and treatment. In order to explore these differences a joint dermatology-podiatry roundtable of onychomycosis experts was convened. Although it has little effect on mycologic cure, debridement may be a valuable adjunct to oral or topical antifungal therapy, especially in patients with greater symptom burden. However, few dermatologists incorporate debridement into their treatment plans and referral to podiatry may be appropriate for some of these patients. Furthermore, podiatrists may be better equipped to manage patients with concurrent diabetes or peripheral vascular disease and elderly patients who are unable to maintain proper foot hygiene. Once cure is achieved, lifestyle and hygiene practices, maintenance/prophylactic onychomycosis treatment, and proactive tinea pedis treatment in patients and family members may help to maintain patients' cured status.

Original languageEnglish (US)
Pages (from-to)1016-1021
Number of pages6
JournalJournal of drugs in dermatology : JDD
Volume14
Issue number9
StatePublished - Sep 1 2015

Fingerprint

Podiatry
Onychomycosis
Dermatology
Joints
Peripheral Vascular Diseases
Debridement
Therapeutics
Hygiene
Tinea Pedis
Life Style
Foot
Referral and Consultation
Maintenance
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Scher, R. K., Tosti, A., Joseph, W. S., Vlahovic, T. C., Plasencia, J., Markinson, B. C., & Pariser, D. M. (2015). Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry Roundtable. Journal of drugs in dermatology : JDD, 14(9), 1016-1021.

Onychomycosis Diagnosis and Management : Perspectives from a Joint Dermatology-Podiatry Roundtable. / Scher, Richard K.; Tosti, Antonella; Joseph, Warren S.; Vlahovic, Tracey C.; Plasencia, Jesse; Markinson, Bryan C.; Pariser, David M.

In: Journal of drugs in dermatology : JDD, Vol. 14, No. 9, 01.09.2015, p. 1016-1021.

Research output: Contribution to journalArticle

Scher, RK, Tosti, A, Joseph, WS, Vlahovic, TC, Plasencia, J, Markinson, BC & Pariser, DM 2015, 'Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry Roundtable', Journal of drugs in dermatology : JDD, vol. 14, no. 9, pp. 1016-1021.
Scher RK, Tosti A, Joseph WS, Vlahovic TC, Plasencia J, Markinson BC et al. Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry Roundtable. Journal of drugs in dermatology : JDD. 2015 Sep 1;14(9):1016-1021.
Scher, Richard K. ; Tosti, Antonella ; Joseph, Warren S. ; Vlahovic, Tracey C. ; Plasencia, Jesse ; Markinson, Bryan C. ; Pariser, David M. / Onychomycosis Diagnosis and Management : Perspectives from a Joint Dermatology-Podiatry Roundtable. In: Journal of drugs in dermatology : JDD. 2015 ; Vol. 14, No. 9. pp. 1016-1021.
@article{3647afd11c6440a185878ca77da87a15,
title = "Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry Roundtable",
abstract = "Onychomycosis prevalence is expected to rise as the population ages and the prevalence of diabetes, peripheral vascular disease, and other significant risk factors rise. Until recently, treatment options were limited due to safety concerns with oral antifungals and low efficacy with available topical agents. Efinaconzole and tavaborole were approved by the FDA in 2014 for onychomycosis treatment and provide additional effective topical treatment options for patients with mild-to-moderate disease. Dermatologists and podiatrists both regularly treat onychomycosis, yet there are striking differences between specialties in approach to diagnosis and treatment. In order to explore these differences a joint dermatology-podiatry roundtable of onychomycosis experts was convened. Although it has little effect on mycologic cure, debridement may be a valuable adjunct to oral or topical antifungal therapy, especially in patients with greater symptom burden. However, few dermatologists incorporate debridement into their treatment plans and referral to podiatry may be appropriate for some of these patients. Furthermore, podiatrists may be better equipped to manage patients with concurrent diabetes or peripheral vascular disease and elderly patients who are unable to maintain proper foot hygiene. Once cure is achieved, lifestyle and hygiene practices, maintenance/prophylactic onychomycosis treatment, and proactive tinea pedis treatment in patients and family members may help to maintain patients' cured status.",
author = "Scher, {Richard K.} and Antonella Tosti and Joseph, {Warren S.} and Vlahovic, {Tracey C.} and Jesse Plasencia and Markinson, {Bryan C.} and Pariser, {David M.}",
year = "2015",
month = "9",
day = "1",
language = "English (US)",
volume = "14",
pages = "1016--1021",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "9",

}

TY - JOUR

T1 - Onychomycosis Diagnosis and Management

T2 - Perspectives from a Joint Dermatology-Podiatry Roundtable

AU - Scher, Richard K.

AU - Tosti, Antonella

AU - Joseph, Warren S.

AU - Vlahovic, Tracey C.

AU - Plasencia, Jesse

AU - Markinson, Bryan C.

AU - Pariser, David M.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Onychomycosis prevalence is expected to rise as the population ages and the prevalence of diabetes, peripheral vascular disease, and other significant risk factors rise. Until recently, treatment options were limited due to safety concerns with oral antifungals and low efficacy with available topical agents. Efinaconzole and tavaborole were approved by the FDA in 2014 for onychomycosis treatment and provide additional effective topical treatment options for patients with mild-to-moderate disease. Dermatologists and podiatrists both regularly treat onychomycosis, yet there are striking differences between specialties in approach to diagnosis and treatment. In order to explore these differences a joint dermatology-podiatry roundtable of onychomycosis experts was convened. Although it has little effect on mycologic cure, debridement may be a valuable adjunct to oral or topical antifungal therapy, especially in patients with greater symptom burden. However, few dermatologists incorporate debridement into their treatment plans and referral to podiatry may be appropriate for some of these patients. Furthermore, podiatrists may be better equipped to manage patients with concurrent diabetes or peripheral vascular disease and elderly patients who are unable to maintain proper foot hygiene. Once cure is achieved, lifestyle and hygiene practices, maintenance/prophylactic onychomycosis treatment, and proactive tinea pedis treatment in patients and family members may help to maintain patients' cured status.

AB - Onychomycosis prevalence is expected to rise as the population ages and the prevalence of diabetes, peripheral vascular disease, and other significant risk factors rise. Until recently, treatment options were limited due to safety concerns with oral antifungals and low efficacy with available topical agents. Efinaconzole and tavaborole were approved by the FDA in 2014 for onychomycosis treatment and provide additional effective topical treatment options for patients with mild-to-moderate disease. Dermatologists and podiatrists both regularly treat onychomycosis, yet there are striking differences between specialties in approach to diagnosis and treatment. In order to explore these differences a joint dermatology-podiatry roundtable of onychomycosis experts was convened. Although it has little effect on mycologic cure, debridement may be a valuable adjunct to oral or topical antifungal therapy, especially in patients with greater symptom burden. However, few dermatologists incorporate debridement into their treatment plans and referral to podiatry may be appropriate for some of these patients. Furthermore, podiatrists may be better equipped to manage patients with concurrent diabetes or peripheral vascular disease and elderly patients who are unable to maintain proper foot hygiene. Once cure is achieved, lifestyle and hygiene practices, maintenance/prophylactic onychomycosis treatment, and proactive tinea pedis treatment in patients and family members may help to maintain patients' cured status.

UR - http://www.scopus.com/inward/record.url?scp=84976286962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976286962&partnerID=8YFLogxK

M3 - Article

C2 - 26355622

AN - SCOPUS:84976286962

VL - 14

SP - 1016

EP - 1021

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 9

ER -